Duncan Hamish Wright

Duncan Hamish Wright, Vice President, Translational Science, Schrödinger Therapeutics Group, joined Schrödinger after almost 20 years at Merck Research Laboratories in roles of increasing responsibility. At Schrödinger, Hamish leads the Translational Science group which encompassess DMPK including PK/PD Modeling & Simulation, Bioanalytical Science and Clinical Biomarkers. Hamish also has a role in Business Development at Schrödinger and works with the BD group on various partnering initiatives. Most recently at Merck, Hamish served as Executive Director, Business Development and Licensing. He was responsible for scientific diligence of licensing opportunities and was a member of the deal team for a number of Merck’s key oncology and immuno oncology transactions.  In previous clinical development and emerging markets roles at Merck, Hamish was a clinical pharmacologist and ran Phase 1 studies for compounds spanning various therapeutic areas including diabetes, obesity, HCV, HIV, heart failure and respiratory disease, to name a few. He also led numerous early clinical programs and had a role as the product development team leader for VANIPREVIR, a novel NS3/4A HCV protease inhibitor, which is now approved and marketed in Japan. Hamish received his Ph.D. in Pharmacology and Therapeutics from McGill University in Montréal, Canada, and holds an academic appointment as Adjunct Associate Professor, Pharmacology and Physiology, at New Jersey Medical School at Rutgers University.